Co-inhibition of TGF-β and PD-L1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance

References

• Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6(1):6. doi:10.1038/srep29765.
   PubMedGoogle Scholar
• Pretzsch E, Bösch F, Neumann J, Ganschow P, Bazhin A, Guba M, Werner J, Angele M. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol. 2019 Sep;19:1–13. doi:10.1155/2019/7407190.
   Google Scholar
• Hammond WA, Swaika A, Mody K. Pharmacologic resistance in colorectal cancer: A review. Ther Adv Med Oncol. 2016 Jan;8(1):57–84. doi:10.1177/1758834015614530.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016 Feb;17(7):10501. doi:10.1038/ncomms10501.
   Google Scholar
• Kim SY, Kim TW. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open. 2020 Mar;55(2):e000634. doi:10.1136/esmoopen-2019-000634.
   PubMed Web of Science ®Google Scholar
• Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis. 2015 Mar;2(1):4–12. doi:10.1016/j.gendis.2014.10.002.
   PubMedGoogle Scholar
• Meng M, Zhong K, Jiang T, Liu Z, Kwan HY, Su T. The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother. 2021 Aug;140:111717. doi:10.1016/j.biopha.2021.111717.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 2021 Oct;21(10):653–667. doi:10.1038/s41577-021-00534-x.
   PubMed Web of Science ®Google Scholar
• Dos Santos W, Sobanski T, de Carvalho AC, Evangelista AF, Matsushita M, Berardinelli GN, de Oliveira MA, Reis RM, Guimarães DP. Mutation profiling of cancer drivers in Brazilian colorectal cancer. Sci Rep. 2019;9(1): doi:10.1038/s41598-019-49611-1.
   Google Scholar
• Philipovskiy A, Ghafouri R, Dwivedi AK, Alvarado L, McCallum R, Maegawa F, Konstantinidis IT, Hakim N, Shurmur S, Awasthi S, et al. Association between tumor mutation profile and clinical outcomes among hispanic-latino patients with metastatic colorectal cancer. Front Oncol. 2022;11:11. doi:10.3389/fonc.2021.772225.
   Google Scholar
• Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017 Feb;17(2):79–92. doi:10.1038/nrc.2016.126.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019 Apr 16;50(4):924–940. doi:10.1016/j.immuni.2019.03.024.
   PubMed Web of Science ®Google Scholar
• Marisa L, Blum Y, Taieb J, Ayadi M, Pilati C, Le Malicot K, Lepage C, Salazar R, Aust D, Duval A, et al. Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer. Clin Cancer Res. 2021;27(17):4768–4780. doi:10.1158/1078-0432.CCR-21-0529.
   PubMed Web of Science ®Google Scholar
• Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, Wouters VM, Roper J, Kendall TJ, Roxburgh CS, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell. 2019 Sep 16;36(3):319–336.e7. doi:10.1016/j.ccell.2019.08.003.
   PubMed Web of Science ®Google Scholar
• Hamarsheh S, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11(1). doi:10.1038/s41467-020-19288-6.
   Web of Science ®Google Scholar
• Kennedy MC, Lowe SW. Mutant p53: it’s not all one and the same. Cell Death Differ. 2022 May;2929(5):983–987. doi:10.1038/s41418-022-00989-y.
   PubMed Web of Science ®Google Scholar
• Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β – an excellent servant but a bad master. J Transl Med. 2012 Sep 3;10(1):183. doi:10.1186/1479-5876-10-183.
   PubMedGoogle Scholar
• Calon A, Espinet E, Palomo-Ponce S, Tauriello DVF, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang X-F, et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22(5):571–584. doi:10.1016/j.ccr.2012.08.013.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538–543. doi:10.1038/nature25492.
   PubMed Web of Science ®Google Scholar
• Spender LC, Ferguson GJ, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, et al. Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor β superfamily type 1 receptors. Mol Pharmacol. 2019;95(2):222–234. doi:10.1124/mol.118.112946.
   PubMed Web of Science ®Google Scholar
• Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, et al. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor. Oncotarget. 2017 Dec 31;9(6):6659–6677. doi:10.18632/oncotarget.23795.
   PubMedGoogle Scholar
• Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020 Sep 18;6(38):eabd2712. doi:10.1126/sciadv.abd2712.
   PubMed Web of Science ®Google Scholar
• Saleh R, Taha RZ, Toor SM, Sasidharan Nair V, Murshed K, Khawar M, Al-Dhaheri M, Petkar MA, Abu Nada M, Elkord E, et al. Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer. Cancer Immunol Immun. 2020;69(10):1989–1999. doi:10.1007/s00262-020-02593-w.
   PubMed Web of Science ®Google Scholar
• Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfirschke C, Voss R, Timke C, Umansky L, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589–602. doi:10.1016/j.ccr.2013.09.014.
   PubMed Web of Science ®Google Scholar
• Guo Y, Li Q, Zhao G, Zhang J, Yuan H, Feng T, Ou D, Gu R, Li S, Li K, et al. Loss of TRIM31 promotes breast cancer progression through regulating K48- and K63-linked ubiquitination of p53. Cell Death Disease. 2021;12(10): doi:10.1038/s41419-021-04208-3.
   Web of Science ®Google Scholar
• Bhullar DS, Barriuso J, Mullamitha S, Saunders MP, O’Dwyer ST, Aziz O. Biomarker concordance between primary colorectal cancer and its metastases. EBioMedicine. 2019;40:363–374. doi:10.1016/j.ebiom.2019.01.050.
   PubMed Web of Science ®Google Scholar
• Filippi CM, Juedes AE, Oldham JE, Ling E, Togher L, Peng Y, Flavell RA, von Herrath MG. Transforming growth factor-β suppresses the activation of CD8+ T-Cells when naive but promotes their survival and function Once antigen experienced. Diabetes. 2008 Oct;57(10):2684–2692. doi:10.2337/db08-0609.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. TGF-β1 attenuates the acquisition and expression of effector function by tumor Antigen-Specific Human Memory CD8 T cells. J Immunol. 2005;174(9):5215–5223. doi:10.4049/jimmunol.174.9.5215.
   PubMed Web of Science ®Google Scholar
• Cottrez F, Groux H. Regulation of TGF-β response during T cell activation is modulated by IL-10. J Immunol. 2001 Jul 15;167(2):773–8. doi:10.4049/jimmunol.167.2.773.
   PubMed Web of Science ®Google Scholar
• Bain CC, Bravo-Blas A, Scott CL, Gomez Perdiguero E, Geissmann F, Henri S, Malissen B, Osborne LC, Artis D, Mowat AM, et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol. 2014 Oct;15(10):929–937. doi:10.1038/ni.2967.
   PubMed Web of Science ®Google Scholar
• Schridde A, Bain CC, Mayer JU, Montgomery J, Pollet E, Denecke B, Milling SWF, Jenkins SJ, Dalod M, Henri S, et al. Tissue-specific differentiation of colonic macrophages requires TGFβ receptor-mediated signaling. Mucosal Immunol. 2017;10(6):1387–1399. doi:10.1038/mi.2016.142.
   PubMed Web of Science ®Google Scholar
• Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Nelson HH, Lynch CF, Pengo T, Thibodeau SN, Church TR, Cerhan JR, et al. Cytotoxic t cells and granzyme b associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidem Biomar. 2017;26(4):622–631. doi:10.1158/1055-9965.EPI-16-0641.
   PubMed Web of Science ®Google Scholar
• de Oliveira GA, Cheng RYS, Ridnour LA, Basudhar D, Somasundaram V, McVicar DW, Monteiro HP, Wink DA. Inducible nitric oxide synthase in the carcinogenesis of gastrointestinal cancers. Antioxid Redox Signal. 2017 Jun 20;26(18):1059–1077. doi:10.1089/ars.2016.6850.
   PubMed Web of Science ®Google Scholar
• Cheng RYS, Ridnour LA, Wink AL, Gonzalez AL, Femino EL, Rittscher H, Somasundaram V, Heinz WF, Coutinho L, Rangel MC, et al. Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome. Cell Death Disease. 2023 May 11;14(5):319. doi:10.1038/s41419-023-05834-9.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu G, Dong B, Piao J, Chen L, Lin Z. The NQO1/PKLR axis promotes lymph node metastasis and breast cancer progression by modulating glycolytic reprogramming. Cancer Lett. 2019;453:170–183. doi:10.1016/j.canlet.2019.03.054.
   PubMed Web of Science ®Google Scholar
• Oh ET, Kim JW, Kim JM, Kim SJ, Lee JS, Hong SS, Goodwin J, Ruthenborg RJ, Jung MG, Lee H-J, et al. NQO1 inhibits proteasome-mediated degradation of HIF-1α. Nat Commun. 2016;7(1): doi:10.1038/ncomms13593.
   Google Scholar
• Walsh CA, Akrap N, Garre E, Magnusson Y, Harrison H, Andersson D, Jonasson E, Rafnsdottir S, Choudhry H, Buffa F, et al. The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer. PLoS One. 2020;15(7):e0236187. doi:10.1371/journal.pone.0236187.
   PubMed Web of Science ®Google Scholar
• Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, et al. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget. 2015;6(29):26909–26921. doi:10.18632/oncotarget.4817.
   PubMedGoogle Scholar
• Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppänen-Laakso T, Virtanen J, Sankila A, Nordling S, Lundin J, Rannikko A, et al. Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins. Oncotarget. 2011;2(12):1176–1190. doi:10.18632/oncotarget.397.
   PubMedGoogle Scholar
• Allain EP, Rouleau M, Lévesque E, Guillemette C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer. 2020 Apr;122122(9):1277–1287. doi:10.1038/s41416-019-0722-0.
   PubMed Web of Science ®Google Scholar
• Sugano T, Seike M, Noro R, Soeno C, Chiba M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, et al. Inhibition of ABCB1 overcomes cancer stem cell–like properties and acquired resistance to MET inhibitors in non–small cell lung cancer. Mol Cancer Ther. 2015;14(11):2433–2440. doi:10.1158/1535-7163.MCT-15-0050.
   PubMed Web of Science ®Google Scholar
• Li Y, Ding Q, Xiong Z, Wen H, Feng C. Overexpression of steroid sulfotransferase genes is associated with worsened prognosis and with immune exclusion in clear cell-renal cell carcinoma. Aging. 2019;11(20):9209–9219. doi:10.18632/aging.102392.
   PubMedGoogle Scholar
• Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, Ferguson MJ, Smith G. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016;115(4):431–441. doi:10.1038/bjc.2016.203.
   PubMed Web of Science ®Google Scholar
• Li X, Liu Z, Zhang A, Han C, Shen A, Jiang L, Boothman DA, Qiao J, Wang Y, Huang X, et al. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nat Commun. 2019;10(1): doi:10.1038/s41467-019-11238-1.
   Google Scholar
• Zhou W, Liu H, Yuan Z, Zundell J, Towers M, Lin J, Lombardi S, Nie H, Murphy B, Yang T, et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell. 2023;41(4):740–756.e10. doi:10.1016/j.ccell.2023.03.002.
   PubMed Web of Science ®Google Scholar
• Zhang F, Liu W, Meng F, Jiang Q, Tang W, Liu Z, Lin X, Xue R, Zhang S, Dong L. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma. J Immunother Cancer. 2024 Jan 25;12(1):e008094. doi:10.1136/jitc-2023-008094.
   PubMed Web of Science ®Google Scholar
• Mehrvarz Sarshekeh A, Lam M, Zorrilla IR, Holliday EB, Das P, Kee BK, Overman MJ, Parseghian CM, Shen JPYC, Tam A, et al. Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer: a phase II trial of bintrafusp alfa in CMS4 metastatic CRC. J Clin Oncol. 2020;38(15_suppl):4084–4084. doi:10.1200/JCO.2020.38.15_suppl.4084.
   Web of Science ®Google Scholar
• Amirkhah R, Gilroy K, Malla SB, Lannagan TRM, Byrne RM, Fisher NC, Corry SM, Mohamed N-E, Naderi-Meshkin H, Mills ML, et al. MmCMS: mouse models’ consensus molecular subtypes of colorectal cancer. Br J Cancer. 2023;128(7):1333–1343. doi:10.1038/s41416-023-02157-6.
   PubMed Web of Science ®Google Scholar
• Cole JJ, Faydaci BA, McGuinness D, Shaw R, Maciewicz RA, Robertson NA, Goodyear CS. Searchlight: automated bulk RNA-seq exploration and visualisation using dynamically generated R scripts. BMC Bioinf. 2021;22(1): doi:10.1186/s12859-021-04321-2.
   PubMed Web of Science ®Google Scholar